We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Spectrum Pharmaceuticals announced Dec. 21 that patent litigation relating to sumatriptan injection, the generic version of GlaxoSmithKline's (GSK) Imitrex Injection, has been dismissed by the U.S. District Court for the District of Delaware pursuant to the previously announced settlement agreement between Spectrum and GSK.
The Quigley Corporation and its wholly owned subsidiary Quigley Pharma announced Dec. 28 that a series of studies were conducted on the advice of Campbell Laboratories, University of Pittsburgh, to assess QR-435 (Quigley Pharma's broad spectrum anti-viral) potential for treating herpes keratitis.
Threshold Pharmaceuticals Dec. 27 announced top-line results from the Phase II clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer.
SciClone Pharmaceuticals and its European partner Sigma-Tau Dec. 28 announced that full patient enrollment is complete for its Phase III clinical trial evaluating the use of Zadaxin in combination with pegylated interferon alpha and ribavirin to treat patients infected with the hepatitis C virus (HCV).
Data from a Phase III study reporting that Tykerb (lapatinib) plus Xeloda (capecitabine) is superior to capecitabine alone in women with HER2-positive advanced breast cancer who had progressed following prior therapy, including Herceptin (trastuzumab), were published in the New England Journal of Medicine.
In observance of the holiday season, FDAnews Drug Pipeline Alert will not be published Monday, Jan. 1. The next issue will be published Tuesday, Jan. 2.
Join FDAnews Tuesday, Jan. 9, for "Pharma Marketing Laws: State by State: Strategies for Compliance with Patchwork Regulations." In this 90-minute interactive audioconference, Keith Korenchuk, attorney with Covington & Burling, will deliver clear guidance on the regulations in the three states (California, Florida and New Hampshire) that enacted new drug marketing laws in 2006, along with the states that already have drug marketing laws in place.